Merck & Co., Inc. (known as MSD outside North America) and Hanmi Pharmaceutical Co., Ltd. have reached an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of non-alcoholic steatohepatitis (NASH), in a deal worth up to $870m.
Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Repurposed Promise In Competitive Indication
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
